Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd2906010.26442/SG29060ArticlesСтатьиResearch ArticleHeart rate in patients with arterial hypertension:a possible marker of high risk or independent therapeutic target?Частота сердечных сокращений у больных артериальной гипертонией: возможный маркер повышенного риска или самостоятельная терапевтическая мишень?KobalavaZh DКобалаваЖанна Давидовна

д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней ФГАОУ ВО РУДН

ShavarovaE KШавароваЕлена Курбановна

канд. мед. наук, доц. каф. пропедевтики внутренних болезней ФГАОУ ВО РУДН

eshavarova@university-cacp.comPeoples’ Friendship University of RussiaФГАОУ ВО Российский университет дружбы народов15062015122VOL 12, NO2 (2015)ТОМ 12, №2 (2015)131809042020Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/29060

The article shows the data concerning the effect of lowering the heart rate (HR) in patients with arterial hypertension (AH), in case of cardiovascular risk reduction in this category of patients. In the routine practice, the high HR can be considered as a possible cardiovascular risk factor, but HR is not included in the basic risk calculators as part of primary prevention. The European AH experts advise to prescribe the drugs with the effect of lowering the heart rate in people with subjective poor tolerance to the tachycardia. The patients should be informed about the beneficial effects of the regular aerobic physical activity concerning the management of HR and BP. The Achieving target BP levels is remained the main priority in the management of patient with hypertensive disease.

В статье приведены данные по влиянию снижения частоты сердечных сокращений (ЧСС) у лиц с артериальной гипертонией (АГ) в отношении снижения сердечно-сосудистого риска у данной категории пациентов. В рутинной практике можно рассматривать повышенную ЧСС как возможный фактор сердечно-сосудистого риска, однако ЧСС не включена в основные калькуляторы риска в рамках первичной профилактики. Европейские эксперты по АГ советуют назначать ритмурежающие препараты лицам с субъективно плохой переносимостью тахикардии. Пациенты должны быть информированы о благотворном влиянии регулярных аэробных физических нагрузок в отношении контроля ЧСС и АД. Достижение целевых цифр АД остается непревзойденным приоритетом в ведении больного с гипертонической болезнью.

arterial hypertensionheart ratethe risk of cardiovascular complicationsартериальная гипертониячастота сердечных сокращенийриск сердечно-сосудистых осложненийLevy R.L, White P.D, Stroud W.D et al. Transient tachycardia: Prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585-8.Dyer A.R, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality findings in three Chicago epidemiological studies. Am J Epidemiol 1980; 112: 736-49.Gillum R.F, Makuc D.M, Feldman J.J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-Up Study. Am Heart J 1991; 121: 171-7.Filipovski J, Ducimetiere P, Safar M.E. Prognostic significance of exercise: blood pressure and heart rate in middle - aged men. Hypertension 1992; 20: 333-9.Willich S.N, Maclure M, Mittleman M et al. Sudden cardiac death: support for a role of triggering in causation. Circulation 1993; 87: 1442-50.Jouven X, Empana J.P, Schwartz P.J et al. Heart-Rate Profile during Exercise as a Predictor of Sudden Death. N Engl J Med 2005; 352: 1951-8.Fujiura Y. Heart rate and mortality in a Japanese general population. An 18-year follow - up study. J Clin Epidemiol 2001; 54: 495-500.Menotti A, Mulder I, Nissinen A et al. Cardiovascular risk factors and 10-year all - cause mortality in elderly European male populations. The FINE study. Eur Heart J 2001; 22: 573-9.Palatini P, Julius S. Review article: heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3-17.Reed D, Mc Gee D, Yano K. Biological and social correlates of blood pressure among Japanese men in Hawaii. Hypertension 1982; 4: 406-14.Cirillo M, Laurenzi M, Trevisan M et al. Haematocrit, blood pressure, and hypertension. The Gubbio Population Study. Hypertension 1992; 20: 319-26.Narkiewicz K, Somers V.K. Interactive effect of heart rate and muscle sympathetic nerve activity on blood pressure. Circulation 1999; 100: 2514-8.Kannel W.B, Wilson P, Blair S.N. Epidemiologic assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985; 109: 876-85.Kannel W.B, Kannel C, Paffenbarger R.S et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.Gillmann M.W, Kannel W.B, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148-54.Palatini P, Thijs L, Staessen J.A et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162 (20): 2313-21.Thomas F, Rudnichi A, Bacri A.M et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37: 1256-61.Mensink G.B.M, Hoffmeister H. The relationship between resting heart rate and all - cause, cardiovascular and cancer mortality. Eur Heart J 1997; 18: 1404-10.Beere P.A, Glacov S, Zarins C.K. Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey: localization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler Thromb 1992; 12: 1245-53.Bassiouny H.S, Zarins C.K, Kadowaki M.H et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994; 19: 426-34.Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423-30.Benetos A, Rudnichi A, Thomas F et al. Influence of Heart Rate on Mortality in a French Population Role of Age, Gender, and Blood Pressure. Hypertension 1999; 33: 44-52.Reunanen A, Karjalainen J, Ristola P et al. Heart rate and mortality. J Intern Med 2000; 247: 231-9.Greenland P, Daviglus M.L, Dyer A.R et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. Am J Epidemiol 1999; 149: 853-62.Jouven X, Desnos M, Guerot C et al. Predicting sudden death in the population: the Paris Prospective Study 1. Circulation 1999; 99: 1978-83.Johansen C.D, Olsen R.H, Pedersen L.R et al. Resting, night - time, and 24 h heart rate as markers of cardiovascular risk in middle - aged and elderly men and women with no apparent heart disease. Eur Heart J 2013; 34: 1732-9.Lee K.L, Woodlief L.H, Topol E.J et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients. GUSTO-I Investigators. Circulation 1995; 91: 1659-68.Copie X, Hnatkova K, Staunton A et al. Predictive power of increased heart rate vs. depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two - year follow - up study. J Am Coll Cardiol 1996; 27: 270-6.Marchioli R, Avanzini F, Barzi F et al. Assessment of absolute risk of death after myocardial infarction by use of multiple - risk - factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22: 2085-103.Berton G.S, Cordiano R, Palmieri R et al. Heart rate during myocardial infarction: relationship with one - year global mortality in men and women. Can J Cardiol 2002; 18: 495-502.Abildstrom S.Z, Jensen B.T, Agner E et al. Heart rate vs. heart rate variability in risk prediction after myocardial infarction. J Cardiovasc Electrophysiol 2003; 14: 168-73.Kovar D, Cannon C.P, Bentley J.H et al. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol 2004; 27: 80-6.Lechat P, Hulot J.S, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103: 1428-33.Linnemann B, Janka H.U. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes 2003; 111: 215-22.Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-10.Singh B.N. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J (Suppl.) 2003; 5: G3-G9.Martin L.J, Comuzzie A.G, Sonnenberg G.E et al. Major quantitative trait locus for resting heart rate maps to a region on chromosome 4. Hypertension 2004; 43: 1146-51.Ranade K, Jorgenson E, Sheu W.H et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935-42.Wilk J.B, Myers R.H, Zhang Y et al. Evidence for a gene influencing heart rate on chromosome 4 among hypertensives. Hum Genet 2002; 111: 207-13.Cook S, Togni M, Schaub M.C et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387-93.Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005; 106: 209-20.Shen W, Ochoa M, Xu X et al. Role of EDRF/NO in parasympathetic coronary vasodilation following carotid chemoreflex activation in conscious dogs. Am J Physiol 1994; 267: H605-H613.Goodson A.R., Leibold J.M., Gutterman D.D. Inhibition of nitric oxide synthesis augments centrally induced sympathetic coronary vasoconstriction in cats. Am J Physiol 1994; 267: H1272- H1278.Hare J.M, Keaney J.F.Jr, Balligand J.L et al. Role of nitric oxide in parasympathetic modulation of beta - adrenergic myocardial contractility in normal dogs. J Clin Invest 1995; 95: 360-6.Hare J.M, Kim B, Flavahan N.A et al. Pertussis toxin - sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart. J Clin Invest 1998; 101: 1424-31.Keaney J.F.Jr, Hare J.M, Balligand J.L et al. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta - adrenergic stimulation. Am J Physiol 1996; 271: H2646-H2652.Chowdhary S, Vaile J.C, Fletcher J et al. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000; 36: 264-9.Vogel C.U, Wolpert C, Wehling M. How to measure heart rate? Eur J Clin Pharmacol 2004; 60: 461-6.Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-10.Mancia G, Bertinieri G, Grassi G et al. Effects of blood pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet 1983; 2: 695-7.Palatini P, Winnicki M, Santonastaso M et al. Reproducibility of heart rate measured in the clinic and with 24-hour intermittent recorders. Am J Hypertens 2000; 13: 92-8.Hozawa A, Inoue R, Ohkubo T et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens 2008; 26: 1571-6.Hansen T.W, Thijs L, Boggia J et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension 2008; 52: 229-35.Sega R, Facchetti R, Bombelli M et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow - up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777-83.Palatini P, Dorigatti F, Zaetta V et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 2006; 24: 1873-80.Palatini P, Casiglia E, Julius S et al. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159: 585-92.Poulter N.R, Dobson J.E, Sever P.S et al. Baseline heart rate, antihypertensive treatment and prevention of cardiovascular outcomes in ASCOT. J Am Coll Cardiol 2009; 54: 1154-61.Pepine C.J, Handberg E.M, Cooper-De Hoff R.M et al. A calcium antagonist vs a non - calcium antagonist hypertension treatment strategy for patient with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005; 366: 895-906.